Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

June 10, 2011  Tags: , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, NuThrax, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

June 7, 2011  Tags: , , , , ,   Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference

ROCKVILLE, Md., May 25, 2011 — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 PM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

June 1, 2011  Tags: , , , , ,   Posted in: Business, El-Hibri, Financial Performance, Healthcare Conference, Investors, fuad el-hibri  No Comments

Emergent BioSolutions Reports Financial Results for First Quarter 2011

ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced  its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]

May 12, 2011  Tags: , , , , ,   Posted in: BioDefense, Biothrax, Business, Chief executive officer, Chief financial officer, Revenue  No Comments

Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial

Total of 2,784 infants vaccinated in TB efficacy trial evaluating MVA85A
Study results expected to be available as early as mid-2012

ROCKVILLE, Md., Apr 28, 2011
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its joint venture with the University of Oxford (Oxford), the Oxford-Emergent Tuberculosis Consortium [...]

May 2, 2011  Tags: , ,   Posted in: Chief executive officer, Emergent BioSolutions, South Africa  No Comments

Emergent BioSolutions Reports Financial Results for Full Year 2010

2010 revenues of $286.2 million
2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
2010 cash, investments and accounts receivable balance of $210.4 million
2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million

Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its [...]

April 13, 2011  Tags: , , , , ,   Posted in: Board of Directors, Business, Chief executive officer, Emergent BioSolutions, Financial Results, fuad el-hibri  No Comments

Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference

Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5, 2011 at 8:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of [...]

April 5, 2011  Tags: , , , ,   Posted in: Board of Directors, El-Hibri, Emergent BioSolutions, Healthcare Conference, fuad, fuad el-hibri  No Comments

Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011

ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for the fourth quarter and full year 2010 on Thursday, March 10, 2011, after market close.
Company management will host a conference call at 5:00 pm Eastern on March 10, 2011 to discuss [...]

February 25, 2011  Tags: , , , , ,   Posted in: Biotechnology and Pharmaceuticals, CEO, Emergent BioSolutions, Research and development, fuad el-hibri  No Comments

Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine

ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]

January 5, 2011  Tags: , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, Research and development, United States Department of Health and Human Services, fuad el-hibri  No Comments

Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting

ROCKVILLE, Md., Dec 06, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral [...]

December 15, 2010  Tags: , , , , , , ,   Posted in: American Society of Hematology, El-Hibri, Emergent BioSolutions, Non-Hodgkin lymphoma, fuad el-hibri  No Comments